Review finds mixed CBN sleep evidence; olive-phenol combination remains untested
Cannabinol for Sleep and Insomnia: A Critical Narrative Review and an Olive-Derived Polyphenol Combination Hypothesis.
AI Summary
This critical narrative review asks whether cannabinol (CBN) has reliable clinical evidence for sleep and insomnia. It assesses three randomized trials in different populations, using oral doses over periods ranging from one night to four weeks. The trials did not consistently find benefits on their primary measures of sleep quality or staying asleep, and dose-ranging signals were sensitive to multiple comparisons, so no optimal dose was identified.
In an acute insomnia trial, 300 mg of CBN was associated with selected secondary sleep benefits, but the abstract also notes concerns about next-day vigilance and simulated driving. Rodent findings involving CBN and its metabolites cannot be directly assumed to apply to people. The review treats an olive-derived phenolic combination as an untested hypothesis: animal and human findings do not establish a distinct sleep benefit from the proposed combination. This abstract-based summary cannot establish that CBN or the combination treats insomnia; the review calls for further product-specific safety and exposure research alongside established insomnia care.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More Sleep research papers you might find interesting.
UK registry study found early PTSD score improvements, then a plateau
A planned pilot trial will test cannabis gummy feasibility for cancer-related…
Review finds strongest evidence in select seizure and MS symptoms
Explore More Research
Stay informed about the latest cannabis science.